 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | YG1699 / Youngene Therap, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Journal: A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type (Pubmed Central) - Mar 8, 2024
YG1699 reduced post-prandial glucose more than dapagliflozin in people with T1D on insulin pump therapy. The results were consistent with dual SGLT1/SGLT2 inhibition by YG1699.
- Inpefa (sotagliflozin) / Lexicon Pharma, YG1699 / Youngene Therap
Effects of YG1699 and Sotagliflozin on Blood Glucose and Urinary Glucose Excretion in SD Rats (Poster Halls B-C; [Board No. 883]) - Apr 10, 2023 - Abstract #ADA2023ADA_1457;
Significant reductions in post-prandial glucose with YG1699 and sotagliflozin are associated with increased UGE. Glucose AUC after 10mg/kg YG1699 was less than 50% of vehicle.
- Inpefa (sotagliflozin) / Lexicon Pharma, YG1699 / Youngene Therap
Effects of YG1699 and Sotagliflozin on Intestinal Glucose Absorption and GLP-1 in Mice (Poster Halls B-C; [Board No. 882]) - Apr 10, 2023 - Abstract #ADA2023ADA_1456;
Background and Aims: YG1699, a dual inhibitor of SGLT1 and SGLT2, recently showed greater glucose reduction than dapagliflozin in patients with type 1 diabetes. YG1699 delays intestinal glucose absorption and induces an incretin response in BALB/c mice, indicating significant gastrointestinal SGLT1 inhibition.
- || YG1699 / Youngene Therap
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: To Evaluate the Safety, Tolerability, and Pharmacokinetics of YG1699?Antidiabetic? in Healthy Chinese Sbjects (clinicaltrials.gov) - Jan 31, 2023
P1, N=31, Completed, Sponsor: Youngene Therapeutics Inc., Ltd.
YG1699 delays intestinal glucose absorption and induces an incretin response in BALB/c mice, indicating significant gastrointestinal SGLT1 inhibition. Recruiting --> Completed | N=20 --> 31 | Trial completion date: May 2022 --> Aug 2022 | Trial primary completion date: Mar 2022 --> Aug 2022
- || YG1699 / Youngene Therap
Trial completion, Trial primary completion date: A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jul 28, 2022
P2, N=19, Completed, Sponsor: Youngene Therapeutics Inc., Ltd.
Recruiting --> Completed | N=20 --> 31 | Trial completion date: May 2022 --> Aug 2022 | Trial primary completion date: Mar 2022 --> Aug 2022 Recruiting --> Completed | Trial primary completion date: Jul 2022 --> Feb 2022
- YG1699 / Youngene Therap, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Post-prandial glucose reduction with YG1699 compared to dapagliflozin in subjects with type 1 diabetes (Short Oral Discussion Area) - Jul 9, 2022 - Abstract #EASD2022EASD_970;
P2
YG1699 reduced post-prandial glucose significantly more than dapagliflozin in subjects with T1D and was well-tolerated in this study. The pattern of lower post-prandial glucose, a greater GLP-1 response, and similar urinary glucose excretion compared to dapagliflozin in the MMTT indicate that YG1699 provided dual inhibition of SGLT1 and SGLT2.
- | YG1699 / Youngene Therap
Trial completion date, Trial primary completion date: A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jun 30, 2022
P2, N=18, Recruiting, Sponsor: Youngene Therapeutics Inc., Ltd.
The pattern of lower post-prandial glucose, a greater GLP-1 response, and similar urinary glucose excretion compared to dapagliflozin in the MMTT indicate that YG1699 provided dual inhibition of SGLT1 and SGLT2. Trial completion date: Apr 2022 --> Jul 2022 | Trial primary completion date: Apr 2022 --> Jul 2022
- | YG1699 / Youngene Therap
Trial primary completion date: A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Feb 9, 2022
P2, N=18, Recruiting, Sponsor: Youngene Therapeutics Inc., Ltd.
Trial completion date: Apr 2022 --> Jul 2022 | Trial primary completion date: Apr 2022 --> Jul 2022 Trial primary completion date: Dec 2021 --> Apr 2022
- || YG1699 / Youngene Therap
Enrollment open, Trial primary completion date: To Evaluate the Safety, Tolerability, and Pharmacokinetics of YG1699?Antidiabetic? in Healthy Chinese Sbjects (clinicaltrials.gov) - Jan 25, 2022
P1, N=20, Recruiting, Sponsor: Youngene Therapeutics Inc., Ltd.
Trial primary completion date: Dec 2021 --> Apr 2022 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2021 --> Mar 2022
- || YG1699 / Youngene Therap
New P1 trial: To Evaluate the Safety, Tolerability, and Pharmacokinetics of YG1699?Antidiabetic? in Healthy Chinese Sbjects (clinicaltrials.gov) - Oct 21, 2021
P1, N=20, Not yet recruiting, Sponsor: Youngene Therapeutics Inc., Ltd.
- || YG1699 / Youngene Therap
Enrollment open: A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jul 19, 2021
P2, N=18, Recruiting, Sponsor: Youngene Therapeutics Inc., Ltd.
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2021 --> Mar 2022 Not yet recruiting --> Recruiting
- YG1699 / Youngene Therap
[VIRTUAL] Yg1699, a novel dual systemic SGLT1 and SGLT2 inhibitor, decreases blood glucose and improves kidney function in primates with diabetic kidney disease (Rome Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_393;
Not yet recruiting --> Recruiting These results are consistent with the mechanism of action of the dual systemic SGLT1 and SGLT2 inhibitor YG1699 and are supportive of a potential for renoprotection in this NHP model of T2D with DKD.
- || YG1699 / Youngene Therap
New P2 trial: A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jul 8, 2021
P2, N=18, Not yet recruiting, Sponsor: Youngene Therapeutics Inc., Ltd.
- ||| YG1699 / Youngene Therap
Trial completion: A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699 (clinicaltrials.gov) - Jan 11, 2021
P1, N=64, Completed, Sponsor: Youngene Therapeutics Inc., Ltd.
These results are consistent with the mechanism of action of the dual systemic SGLT1 and SGLT2 inhibitor YG1699 and are supportive of a potential for renoprotection in this NHP model of T2D with DKD. Recruiting --> Completed
- YG1699 / Youngene Therap
[VIRTUAL] First-in-Human Study of YG1699, an SGLT1 and SGLT2 Dual Transporter Inhibitor () - May 18, 2020 - Abstract #ADA2020ADA_3037;
P1
The data also show that YG1699 has adequate half-life that can support once daily dosing in Phase II clinical trials. Adverse events were low and generally mild and no SAEs were observed.
- ||| YG1699 / Youngene Therap
Enrollment open, Trial completion date, Trial primary completion date: A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699 (clinicaltrials.gov) - Mar 2, 2020
P1, N=64, Recruiting, Sponsor: Youngene Therapeutics Inc., Ltd.
Adverse events were low and generally mild and no SAEs were observed. Completed --> Recruiting | Trial completion date: Nov 2019 --> Jun 2020 | Trial primary completion date: Nov 2019 --> Apr 2020
- ||| YG1699 / Youngene Therap
Trial completion, Trial completion date: A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699 (clinicaltrials.gov) - Nov 18, 2019
P1, N=64, Completed, Sponsor: Youngene Therapeutics Inc., Ltd.
Completed --> Recruiting | Trial completion date: Nov 2019 --> Jun 2020 | Trial primary completion date: Nov 2019 --> Apr 2020 Recruiting --> Completed | Trial completion date: Feb 2020 --> Nov 2019
- | YG1699 / Youngene Therap
New P1 trial: A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699 (clinicaltrials.gov) - May 15, 2019
P1, N=64, Recruiting, Sponsor: Youngene Therapeutics Inc., Ltd.